rs148195424
Positions:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4BP6BS2
The NM_174936.4(PCSK9):c.709C>T(p.Arg237Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00107 in 1,613,120 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00065 ( 0 hom., cov: 35)
Exomes 𝑓: 0.0011 ( 0 hom. )
Consequence
PCSK9
NM_174936.4 missense
NM_174936.4 missense
Scores
1
12
6
Clinical Significance
Conservation
PhyloP100: 1.33
Genes affected
PCSK9 (HGNC:20001): (proprotein convertase subtilisin/kexin type 9) This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.27151805).
BP6
Variant 1-55052701-C-T is Benign according to our data. Variant chr1-55052701-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 265933.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=6, Uncertain_significance=9}.
BS2
High AC in GnomAd4 at 99 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCSK9 | NM_174936.4 | c.709C>T | p.Arg237Trp | missense_variant | 5/12 | ENST00000302118.5 | NP_777596.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCSK9 | ENST00000302118.5 | c.709C>T | p.Arg237Trp | missense_variant | 5/12 | 1 | NM_174936.4 | ENSP00000303208 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000650 AC: 99AN: 152224Hom.: 0 Cov.: 35
GnomAD3 genomes
AF:
AC:
99
AN:
152224
Hom.:
Cov.:
35
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000719 AC: 179AN: 249096Hom.: 0 AF XY: 0.000666 AC XY: 90AN XY: 135140
GnomAD3 exomes
AF:
AC:
179
AN:
249096
Hom.:
AF XY:
AC XY:
90
AN XY:
135140
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00111 AC: 1620AN: 1460778Hom.: 0 Cov.: 81 AF XY: 0.00104 AC XY: 757AN XY: 726698
GnomAD4 exome
AF:
AC:
1620
AN:
1460778
Hom.:
Cov.:
81
AF XY:
AC XY:
757
AN XY:
726698
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000650 AC: 99AN: 152342Hom.: 0 Cov.: 35 AF XY: 0.000618 AC XY: 46AN XY: 74492
GnomAD4 genome
AF:
AC:
99
AN:
152342
Hom.:
Cov.:
35
AF XY:
AC XY:
46
AN XY:
74492
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
4
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
14
ExAC
AF:
AC:
72
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:11Benign:7
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Hypercholesterolemia, autosomal dominant, 3 Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-Foix | Dec 16, 2016 | subjects mutated among 2600 FH index cases screened = 2, family member = 1 / Software predictions: Damaging - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Oct 26, 2021 | The c.709C>T (p.Arg237Trp) variant identified in the PCSK9 gene substitutes a conserved Arginine for Tryptophan at amino acid 237/693 (exon5/12). This variant is found in 99 heterozygotes in gnomAD(v3.1.1) (0 homozygotes; allele frequency:6.5e-4), which is slightly higher than expected for a pathogenic Familial Hypercholesterolemia associated variant (ClinGen Familial Hypercholesterolemia Expert Panel Specifications, Version 1.1). In silico algorithms predict this variant to be Pathogenic (REVEL; score:0.615) and Damaging (SIFT; score:0.001) to the function of the canonical transcript. This variant is reported in ClinVar as both a Variant of Uncertain Significance and Likely Benign (VarID:265933). The p.Arg237Trp variant has been reported in individuals in the literature with hypercholesterolemia [PMID:26020417, 18262190, 16465619, 33418990], but has also been identified in many individuals with hypocholesterolemia [PMID:29459468,24507775, 20623344, 16424354, others]. Functional studies on the role of this variant to PCSK9 function are conflicting, with some studies suggesting no damaging effect on PCSK9 [PMID:15358785, 29259136], and another suggesting mild increase in LDL receptor and higher LDL internalization possibly due to failure to undergo autocatalytic cleavage [PMID:16571601]. The p.Arg237 residue is within the Peptidase S8 domain of PCSK9 (UniProtKB:Q8NBP7). Given the conflicting informationregarding the c.709C>T (p.Arg237Trp) variant identified in the PCSK9 gene, it is reported as a Variant of Uncertain Significance. - |
not provided Uncertain:2Benign:2
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2023 | PCSK9: BS1 - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 28, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 26, 2022 | Also identified in patients with hypercholesterolemia in published literature (de Paiva Silvino et al., 2020; Gill et al., 2021; Meshkov et al., 2021); at least one patient also harbored a pathogenic variant in the LDLR gene (Wang et al., 2016); Published functional studies demonstrate loss-of-function with a modest effect, resulting in a 16% increased level of cell surface LDL-receptors and a 35% increase in the internalization of LDL when compared to wild-type PCSK9 (Cameron et al., 2006); This variant is associated with the following publications: (PMID: 18300938, 25046268, 16424354, 16465619, 17765244, 21943799, 28157721, 17435765, 16912035, 15358785, 24507775, 27535533, 16571601, 26582918, 27765764, 33418990, 33231818, 33303402) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 09, 2019 | - - |
Hypercholesterolemia, familial, 1 Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Robarts Research Institute, Western University | Aug 22, 2019 | - - |
Uncertain significance, criteria provided, single submitter | research | Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge | Mar 01, 2016 | 0/190 non-FH alleles (portuguese normolipidemic individuals); 0/100 normolipidemic individuals - |
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Aug 01, 2016 | Found in patient having exome sequencing for an unrelated indication. No known history of hyperlipidemia. - |
not specified Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 16, 2021 | Variant summary: PCSK9 c.709C>T (p.Arg237Trp) results in a non-conservative amino acid change located in the Peptidase S8/S53 domain (IPR000209) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00072 in 249096 control chromosomes. The observed variant frequency is approximately 19 fold of the estimated maximal expected allele frequency for a pathogenic variant in PCSK9 causing Familial Hypercholesterolemia phenotype (3.8e-05), strongly suggesting that the variant is benign. c.709C>T has been reported in the literature in sequencing studies of individuals affected with hypercholesterolemia (e.g. Kotowski_2006, Homer_2008, Madeiros_2016, Berge_2006, Cameron_2008, Leren_2008, Lange_2014, Benn_2017, Balder_2018) without strong evidence for causality. These reports do not provide unequivocal conclusions about association of the variant with Familial Hypercholesterolemia. At-least one co-occurrence with another pathogenic variant causative of Familial Hypercholesterolemia has been observed at our laboratory (LDLR c.2043C>A, p.Cys681*), providing supporting evidence for a benign role. Several publications report experimental evidence evaluating an impact on protein function. One group reports little to no damaging effects for the variant in the processing and secretion of PCSK9 protein (Benjannet_2004, Benjannet_2006). Another study reports a very mild increase in the expression of LDL receptor on the cell surface and slightly higher levels of LDL internalization in cells with the variant (Cameron_2006). Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign, n=2; VUS, n=6). Based on the evidence outlined above, the variant was classified as likely benign. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Short fetal femur length Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Phenosystems SA | - | - - |
Hypobetalipoproteinemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
PCSK9-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 02, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 30, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Familial hypercholesterolemia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Aug 23, 2019 | This variant has been identified in 0.2200% (62/28178) of Color clients and in 0.1327% (47/35392) of Latino population in the Genome Aggregation Database (gnomAD). This variant allele frequency is greater than expected for PCSK9-related disorders based on prevalence, penetrance, and genetic heterogeneity. Therefore, this variant is classified as Likely Benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
D
LIST_S2
Uncertain
D
M_CAP
Uncertain
D
MetaRNN
Benign
T
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at